$DGX

PREVOZNIK MICHAEL E sold $5.5M of DGX

PREVOZNIK MICHAEL E (SVP & General Counsel) sold 22,677 shares of QUEST DIAGNOSTICS INC (DGX) at an average of $243.11 ($242.88–$244.51, $5.51M total) across 3 trades on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PREVOZNIK MICHAEL E
Published Aug 31, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Bearish
medium confidence
Mentioned
$DGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXBearishMed
01

Why it matters

The disclosed sale provides fresh data on insider sentiment and may influence short‑term price action.

02

Market read

First‑report insider sale of $5.5 M; relevant for traders monitoring DGX.

03

What to watch

Potential upcoming earnings release could offset the negative sentiment from the insider sale.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑28

Background

SEC Form 4 filing discloses insider transaction for Quest Diagnostics (DGX).

Company-level read

Ticker impact

$DGXBearishMedium confidence
Context

SVP & General Counsel sold 22,677 shares for $5.5M via a 10b5‑1 plan

Expected impact

Possible short‑term dip as market digests the $5.5M sale.

Evidence & confidence

A senior officer off‑loading a sizable stake signals reduced confidence; however, the sale is pre‑arranged under a 10b5‑1 plan, limiting immediate informational value.

Market effects

Minimal impact on healthcare diagnostics sector; insider activity is company‑specific.

U.S. market only; no broader regional effect.

Low global relevance.

Counterpoint

The sale may be purely portfolio rebalancing under a 10b5‑1 plan, not a bearish signal.

Key entities

  • Quest Diagnostics Inc.

    Issuer of the Form 4 filing.

  • Michael E. Prevoznick

    SVP & General Counsel, insider seller.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXMed

New York State Data Exposed Following Quest Diagnostic Breach

Quest Diagnostics disclosed a data breach in its Quanum Lab Services Manager system, exposing patient records, including names, Social Security numbers, and medical information. The breach was contained, but the exact number of affected individuals is still under investigation. Quest will notify impacted patients and offer identity theft monitoring services. The company serves 1 in 3 American adults annually.

$DGXMed

Quest Diagnostics says unauthorized access to lab-ordering system exposed patient records

Quest Diagnostics reported unauthorized access to its Quanum Lab Services Manager system, exposing patient records. The breach was discovered on Oct. 21, 2026, and disclosed the next day. The company is investigating with outside experts and has notified law enforcement. No disruption to customer operations was reported, and no threat group has claimed responsibility. Quest has temporarily paused access to affected systems and recommended alternative methods for orders and results.

$DGXLow

Medical Testing Giant Quest Diagnostics Confirms Massive Security Breach Exposing Sensitive Patient Records Amid a Coordinated Global Hacking Surge

Quest Diagnostics confirmed a security breach exposing patient records via its Quanum Lab Services Manager system. The breach, discovered on October 21, impacted protected health information and personal data. The company has taken steps to contain the breach, but the full extent of the damage is still under investigation. This incident is part of a broader surge in global cyberattacks, including a critical flaw in the PHP programming language.

$DGXMedAI 8/10

Quest Diagnostics Q3 2026 Revenue Rises to $3.1B, Diluted EPS Up to $2.78

Quest Diagnostics reported Q3 2026 revenue of $3.1B, up 10% YoY, with diluted EPS rising to $2.78. Operating income increased to $479M. Year-to-date revenue reached $9.035B, with net income attributable to Quest at $884M. The company maintained strong cash flow and returned capital through buybacks and dividends, but noted rising operating costs and debt.